134 related articles for article (PubMed ID: 28546502)
21. Cytokine neutralization at specific cellular source : A new therapeutic paradigm?
Kruglov AA; Nedospasov SA
Z Rheumatol; 2017 Mar; 76(Suppl 1):22-24. PubMed ID: 27787607
[TBL] [Abstract][Full Text] [Related]
22. [IL-6 as a target in autoimmune disease and inflammation].
Hashizume M; Ohsugi Y
Nihon Yakurigaku Zasshi; 2014 Oct; 144(4):172-7. PubMed ID: 25312286
[No Abstract] [Full Text] [Related]
23. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
24. Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders.
Tougaard P; Zervides KA; Skov S; Hansen AK; Pedersen AE
Immunopharmacol Immunotoxicol; 2016; 38(1):29-38. PubMed ID: 26810853
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
Edwards CK; Zhou T; Zhang J; Baker TJ; De M; Long RE; Borcherding DR; Bowlin TL; Bluethmann H; Mountz JD
J Immunol; 1996 Aug; 157(4):1758-72. PubMed ID: 8759766
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-6: Biology, signaling and strategies of blockade.
Schaper F; Rose-John S
Cytokine Growth Factor Rev; 2015 Oct; 26(5):475-87. PubMed ID: 26189695
[TBL] [Abstract][Full Text] [Related]
27. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases.
Williams RO; Paleolog E; Feldmann M
Curr Opin Pharmacol; 2007 Aug; 7(4):412-7. PubMed ID: 17627887
[TBL] [Abstract][Full Text] [Related]
28. Anti-TNF-alpha antibody therapies in autoimmune diseases.
Chatzantoni K; Mouzaki A
Curr Top Med Chem; 2006; 6(16):1707-14. PubMed ID: 17017952
[TBL] [Abstract][Full Text] [Related]
29. [Off-label use of biological therapies in systemic diseases].
Hachulla E
Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
[No Abstract] [Full Text] [Related]
30. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
31. Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells.
Wu SH; Lu C; Dong L; Zhou GP; He ZG; Chen ZQ
Kidney Int; 2005 Jul; 68(1):35-46. PubMed ID: 15954894
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of IL-8, LIF (pro-inflammatory) and IL-11 (anti-inflammatory) on TNF-alpha-induced PGE(2)release and on signalling pathways in human OA synovial fibroblasts.
Alaaeddine N; Di Battista JA; Pelletier JP; Kiansa K; Cloutier JM; Martel-Pelletier J
Cytokine; 1999 Dec; 11(12):1020-30. PubMed ID: 10623427
[TBL] [Abstract][Full Text] [Related]
33. Alcohol (ethanol) inhibits IL-8 and TNF: role of the p38 pathway.
Arbabi S; Garcia I; Bauer GJ; Maier RV
J Immunol; 1999 Jun; 162(12):7441-5. PubMed ID: 10358198
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways.
Carlson NG; Wieggel WA; Chen J; Bacchi A; Rogers SW; Gahring LC
J Immunol; 1999 Oct; 163(7):3963-8. PubMed ID: 10490998
[TBL] [Abstract][Full Text] [Related]
35. Potential target of infliximab in autoimmune and inflammatory diseases.
Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
[TBL] [Abstract][Full Text] [Related]
36. Plasticity and cross-talk of interleukin 6-type cytokines.
Garbers C; Hermanns HM; Schaper F; Müller-Newen G; Grötzinger J; Rose-John S; Scheller J
Cytokine Growth Factor Rev; 2012 Jun; 23(3):85-97. PubMed ID: 22595692
[TBL] [Abstract][Full Text] [Related]
37. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
38. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
39. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
40. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models.
Kruglov AA; Kuchmiy A; Grivennikov SI; Tumanov AV; Kuprash DV; Nedospasov SA
Cytokine Growth Factor Rev; 2008; 19(3-4):231-44. PubMed ID: 18502680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
